Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

SIM0689

Drug and asset intelligence for SIM0689 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
1
Catalysts
1
Stage
Development stage unavailable

Sponsor company

Jiangsu Simcere Pharmaceutical Co., Ltd. →

Recent signals(1)

ClinicalJune 23, 2026

Phase 1 Study of SIM0689 for Advanced Solid Tumors Initiated by Jiangsu Simcere

A Phase 1 study of SIM0689 is underway to evaluate its safety and early efficacy in adult patients with advanced solid tumors.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Jiangsu Simcere Pharmaceutical Co., Ltd. — SIM0689

Key milestones include dose escalation results and initial efficacy data from the trial.

June 23, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Oncology →
Oncology · Solid Tumors →
Solid Tumors →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.